{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:46:18Z","timestamp":1793018778785,"version":"4.5.0"},"reference-count":46,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["300432"],"award-info":[{"award-number":["300432"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14760584.2026.2641671","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:56:31Z","timestamp":1772729791000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study"],"prefix":"10.1080","volume":"25","author":[{"given":"Maria Jo\u00e3o","family":"Fonseca","sequence":"first","affiliation":[{"name":"GSK","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislava","family":"Bratkovi\u0107","sequence":"additional","affiliation":[{"name":"GSK","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus","family":"\u00c7olak","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital \u2013 Herlev and Gentofte","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Helleberg","sequence":"additional","affiliation":[{"name":"Rigshospitalet \u2013 Copenhagen University Hospital","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Vestbo","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital \u2013 Herlev and Gentofte","place":["Copenhagen, Denmark"]},{"name":"University of Manchester","place":["Manchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Burns","sequence":"additional","affiliation":[{"name":"GSK","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Spanggaard","sequence":"additional","affiliation":[{"name":"EY Parthenon","place":["Frederiksberg, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"L\u00f8we Lundgren","sequence":"additional","affiliation":[{"name":"EY Parthenon","place":["Frederiksberg, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Gkalapi","sequence":"additional","affiliation":[{"name":"GSK","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Theiss-Nyland","sequence":"additional","affiliation":[{"name":"GSK","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.21101\/cejph.a6861"},{"key":"e_1_3_8_4_1","unstructured":"Centers for Disease Control and Prevention. Respiratory syncytial virus infection in adults. [cited 2025 Nov 5]. Available from: https:\/\/www.cdc.gov\/rsv\/adults\/index.html"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13031"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit471"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12855"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab040"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0105-2022"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-025-01194-w"},{"key":"e_1_3_8_11_1","article-title":"Clinical and economic burden of respiratory syncytial virus in adults with acute respiratory infections \u2013 a Danish nationwide cohort study","author":"Fonseca MJ","year":"2025","unstructured":"Fonseca MJ, Bratkovi\u0107 S, Vestergaard Dich N. Clinical and economic burden of respiratory syncytial virus in adults with acute respiratory infections \u2013 a Danish nationwide cohort study. ESCMID Global Vienna (Austria). 2025.","journal-title":"ESCMID Global Vienna (Austria)"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad510"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad471"},{"key":"e_1_3_8_14_1","unstructured":"European Medicines Agency. Arexvy. [cited 2026 Jan 26]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/arexvy"},{"key":"e_1_3_8_15_1","unstructured":"European Medicines Agency. Abrysvo. [cited 2026 Jan 26]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo"},{"key":"e_1_3_8_16_1","unstructured":"European Medicines Agency. mResvia. [cited 2026 Jan 26]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mresvia"},{"key":"e_1_3_8_17_1","unstructured":"Food and Drug Administration. Arexvy. [cited 2026 Jan 26]. Available from: https:\/\/www.fda.gov\/media\/167805\/download"},{"key":"e_1_3_8_18_1","unstructured":"Food and Drug Administration. Abrysvo. [cited 2026 Jan 26]. Available from: https:\/\/www.fda.gov\/media\/168889\/download?attachment"},{"key":"e_1_3_8_19_1","unstructured":"Food and Drug Administration. mRESVIA - full prescribing information. [cited 2026 Jan 26]. Available from: https:\/\/www.fda.gov\/media\/179005\/download?attachmentfiles\/4307\/abrysvo.html"},{"key":"e_1_3_8_20_1","unstructured":"Joint Committee on Vaccination and Immunisation. Respiratory syncytial virus (RSV) immunisation programme for adults aged 80 years and older: JCVI advice 16 July 2025. [cited 2026 Jan 26]. Available from: https:\/\/www.gov.uk\/government\/publications\/rsv-immunisation-programme-jcvi-advice-16-july-2025\/respiratory-syncytial-virus-rsv-immunisation-programme-for-adults-aged-80-years-and-older-jcvi-advice-16-july-2025"},{"key":"e_1_3_8_21_1","unstructured":"STIKO. Vaccination recommen\u00addations by STIKO. [cited 2026 Jan 26]. Available from: https:\/\/www.rki.de\/EN\/Topics\/Infectious-diseases\/Immunisation\/STIKO\/STIKO-recommendations\/recommendations_content.html"},{"key":"e_1_3_8_22_1","unstructured":"Danish Medical Association. PLO\u2019rientering 14\/2024. [cited 2026 Jan 26]. Available from: https:\/\/laeger.dk\/foreninger\/plo\/plorientering\/plorientering-142024"},{"key":"e_1_3_8_23_1","unstructured":"Sundhedsstyrelsen. Tilskud til vacciner til visse persongrupper. [cited 2026 Jan 26]. Available from: https:\/\/www.sst.dk\/vidensbase\/forebyggelse\/vaccination\/tilskud-til-vacciner-til-visse-persongrupper"},{"key":"e_1_3_8_24_1","unstructured":"Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. 2024 GOLD report. [cited 2025 Dec 19]. Available from: https:\/\/goldcopd.org\/2024-gold-report\/"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1624007"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(25)00048-7"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2539887"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae010"},{"issue":"3","key":"e_1_3_8_29_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1473-3099(25)00546-8","article-title":"Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75\u201379 years in England: a multicentre, test-negative, case-control study","volume":"26","author":"Symes R","year":"2025","unstructured":"Symes R, Whitaker HJ, Ahmad S, et al. Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75\u201379 years in England: a multicentre, test-negative, case-control study. Lancet Infect Dis. 2025;26(3): 229\u2013238.","journal-title":"Lancet Infect Dis"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.6355"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.8322"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01738-0"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/v17111407"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa730"},{"key":"e_1_3_8_35_1","unstructured":"Vaccine effectiveness of a bivalent RSV prefusion F protein-based vaccine for preventing RSV hospitalizations in adults (DAN-RSV) - NCT06684743. [cited 2026 Jan 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06684743"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1427550"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2535755"},{"key":"e_1_3_8_38_1","unstructured":"UK Health Security Agency. RSV vaccine coverage report in older adults in England: September 2025. [cited 2026 Jan 26]. Available from: https:\/\/www.gov.uk\/government\/publications\/rsv-older-adults-vaccination-coverage-in-england\/rsv-vaccine-coverage-report-in-older-adults-in-england-september-2025"},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf434"},{"key":"e_1_3_8_40_1","unstructured":"World Health Organization. WHO global market study on RSV immunization products. 2024."},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2024.2441867"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00455-9"},{"key":"e_1_3_8_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01082-2"},{"key":"e_1_3_8_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2841"},{"key":"e_1_3_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00796-5"},{"key":"e_1_3_8_46_1","volume-title":"9th ReSVINET Conference","author":"Singer D","year":"2026","unstructured":"Singer D, Steffens A, La E, et al. Effectiveness of adjuvanted RSVPreF3 vaccine in preventing major adverse cardiovascular events, severe asthma exacerbations, and severe COPD exacerbations among US adults aged 60 years and older. In: 9th ReSVINET Conference; Rome, Italy; 2026."},{"key":"e_1_3_8_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1474045"},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2025.111737"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2026.2641671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:07:44Z","timestamp":1773202064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2026.2641671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14760584.2026.2641671"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2026.2641671","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2641671"}}